Individualized management of advanced bladder cancer: Where do we stand?
Burgess EF. Urol Oncol. 2013 Dec 11. pii: S1078-1439(13)00399-2. doi: 10.1016/j.urolonc.2013.09.019. [Epub ahead of print]

Author information

Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC. Electronic address: earle.burgess@carolinas.org.

Abstract

Despite recent progress in the development of novel targeted therapies in various malignancies, the management of advanced urothelial cancer has changed little over the past 2 decades. Comorbidities inherent to patients with bladder cancer often preclude the use of standard cisplatin-based chemotherapy and underscore the need for individualized treatment recommendations and the development of more effective therapies. This review discusses current issues relevant to the management of patients with locally advanced and metastatic urothelial carcinoma of the bladder and highlights recent advances in defining molecular aberrations that may ultimately lead to personalized therapeutic decision making.